• Home
  • About
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
  • Pipeline
  • Science
    • Quatramer
    • TridentAI
  • Investors
  • Contact Us
Hillstream
  • Home
  • About
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
  • Pipeline
  • Science
    • Quatramer
    • TridentAI
  • Investors
  • Contact Us
    Loading posts...
  • Hillstream BioPharma Announces Pricing of Initial Public Offering

    Hillstream BioPharma Announces Pricing of Initial Public Offering January 11th, 2022 BRIDGEWATER, NJ / ACCESSWIRE / January 11, 2022 / Hillstream BioPharma, Inc. (NASDAQ:HILS) ("Hillstream", the "Company"), a biotechnology company developing novel therapeutic…
    January 11, 2022
    Announcement
  • Hillstream Selected to Present at the 2021 BioConnect Virtual Conference Hosted by H.C. Wainwright

    Hillstream Selected to Present at the 2021 BioConnect Virtual Conference Hosted by H.C. Wainwright January 11th, 2021 Bridgewater, New Jersey - Hillstream BioPharma, Inc. (“Hillstream”), a clinical- stage biotechnology company leveraging its…
    January 11, 2021
    Announcement
  • Hillstream BioPharma’s HSB-888 Receives Rare Pediatric Disease Designation and Orphan Drug Designation for Osteosarcoma

    Hillstream BioPharma’s HSB-888 Receives Rare Pediatric Disease Designation and Orphan Drug Designation for Osteosarcoma November 23rd, 2020 Osteosarcoma remains the most common primary pediatric bone malignancy mostly occurring in adolescents for which…
    November 23, 2020
    Announcement
  • Hillstream BioPharma Announces Richard M. Stone, MD as New Member to Scientific Advisory Board

    Hillstream BioPharma Announces Richard M. Stone, MD as New Member to Scientific Advisory Board November 18th, 2020 Hillstream BioPharma Announces Richard M. Stone, MD as New Member to Scientific Advisory Board Expertise…
    November 18, 2020
    Announcement
  • Hillstream BioPharma Announces Renewal of CRADA with National Center for Advancing Translational Sciences for Use of Quatramer™ Technology with HDAC6-PI3Kδ Dual Inhibitor for AML

    Hillstream BioPharma Announces Renewal of CRADA with National Center for Advancing Translational Sciences for Use of Quatramer™ Technology with HDAC6-PI3Kδ Dual Inhibitor for AML November 2nd, 2020 Hillstream BioPharma Announces Renewal of…
    November 2, 2020
    Announcement
  • Hillstream BioPharma to Participate in Panel During 2020 NORD Rare Diseases and Orphan Products Breakthrough Summit 2020

    Hillstream BioPharma Completes Pre-IND Review with FDA on HSB-1216 for Small Cell Lung Cancer (SCLC) October 1st, 2020  Bridgewater, New Jersey, October 21, 2020 – Hillstream BioPharma Inc. (“Hillstream”, the “Company”), a…
    October 21, 2020
    Announcement
  • Hillstream BioPharma to Participate in Panel During 2020 NORD Rare Diseases and Orphan Products Breakthrough Summit 2020

    HillstreaHillstream BioPharma to Participate in Panel During 2020 NORD Rare Diseases and Orphan Products Breakthrough Summit 2020 October 1st, 2020 Hillstream BioPharma to Participate in Panel During 2020 NORD Rare Diseases and…
    October 5, 2020
    Announcement
  • Hillstream BioPharma to Present at the Tenth Annual BioNJ BioPartnering Virtual Conference

    Hillstream BioPharma to Present at the Tenth Annual BioNJ BioPartnering Virtual Conference October 1st, 2020 Hillstream BioPharma to Present at the Tenth Annual BioNJ BioPartnering Virtual Conference Bridgewater, New Jersey, October 1,…
    October 1, 2020
    Announcement
  • Hillstream BioPharma to Present at the World Orphan Drug Conference USA 2020

    Hillstream BioPharma to Present at the World Orphan Drug Conference USA 2020 August 17th, 2020 Hillstream BioPharma to Present at the World Orphan Drug Conference USA 2020  Chester, New Jersey, August 17,…
    August 17, 2020
    Announcement
  • Hillstream BioPharma Presentations at 2020 AACR Virtual Annual Meeting II

    Hillstream BioPharma Presentations at 2020 AACR Virtual Annual Meeting II FEBRUARY 10, 2020 Abstracts highlight data from HSB-1216 (Salinomycin QUATRAMER™) in small cell lung cancer and triple negative breast cancer Chester, NJ…
    May 19, 2020
    Announcement
Show more All posts are shown

Recent Posts

  • Hillstream BioPharma to Present at BioNJ’s 12th Annual BioPartnering Virtual Conference Held on May 9- 13, 2022
  • Hillstream BioPharma R&D Day Highlights Ferroptosis, the Non-Genetic Novel, Emerging Mechanism of Action, Targeting Drug Resistant and Devastating Cancers
  • February 24, 2022 Hillstream R & D Day 8:00 AM – Targeting Ferroptosis to Iron Out Resistant Cancers
  • Hillstream BioPharma Receives Orphan Drug Designation for HSB-1216 for the Treatment of Uveal Melanoma
  • Hillstream BioPharma Provides Business Review with Key Pipeline Updates

Address:

245 Main St., Ste. 204
Chester, NJ

Tel: +1 (917) 214-3514
Mail: info@hillstreambio.com
Hillstream Biopharma

1200 Route 22 East
Suite 2000
Bridgewater, NJ 08807

Tel: 1-908-955-3140
Mail: info@hillstreambio.com

Latest News

  • Hillstream BioPharma to Present at BioNJ’s 12th Annual BioPartnering Virtual Conference Held on May 9- 13, 2022 May 6, 2022
  • Hillstream BioPharma R&D Day Highlights Ferroptosis, the Non-Genetic Novel, Emerging Mechanism of Action, Targeting Drug Resistant and Devastating Cancers March 2, 2022
  • February 24, 2022 Hillstream R & D Day 8:00 AM – Targeting Ferroptosis to Iron Out Resistant Cancers February 22, 2022

© Copyright 2022. Hillstream Biopharma, Inc. All Rights Reserved